GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OCSE:BAVA) » Definitions » Cyclically Adjusted PS Ratio

Bavarian Nordic A/S (OCSE:BAVA) Cyclically Adjusted PS Ratio : 4.52 (As of Jun. 09, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Bavarian Nordic A/S Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Bavarian Nordic A/S's current share price is kr180.75. Bavarian Nordic A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr40.00. Bavarian Nordic A/S's Cyclically Adjusted PS Ratio for today is 4.52.

The historical rank and industry rank for Bavarian Nordic A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCSE:BAVA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.49   Med: 6.18   Max: 13.57
Current: 4.52

During the past years, Bavarian Nordic A/S's highest Cyclically Adjusted PS Ratio was 13.57. The lowest was 3.49. And the median was 6.18.

OCSE:BAVA's Cyclically Adjusted PS Ratio is ranked better than
55.16% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs OCSE:BAVA: 4.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bavarian Nordic A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was kr10.897. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr40.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bavarian Nordic A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Bavarian Nordic A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Cyclically Adjusted PS Ratio Chart

Bavarian Nordic A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.18 6.64 8.87 6.28 4.51

Bavarian Nordic A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.56 5.32 4.23 4.51 3.87

Competitive Comparison of Bavarian Nordic A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Bavarian Nordic A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bavarian Nordic A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic A/S's Cyclically Adjusted PS Ratio falls into.



Bavarian Nordic A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bavarian Nordic A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=180.75/40
=4.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bavarian Nordic A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Bavarian Nordic A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=10.897/118.4000*118.4000
=10.897

Current CPI (Mar. 2024) = 118.4000.

Bavarian Nordic A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.978 99.700 5.912
201409 6.776 99.700 8.047
201412 14.189 99.400 16.901
201503 6.549 100.200 7.739
201506 11.037 100.300 13.029
201509 2.270 100.200 2.682
201512 7.654 99.800 9.080
201603 0.638 100.200 0.754
201606 3.219 100.600 3.789
201609 11.705 100.200 13.831
201612 10.340 100.300 12.206
201703 5.169 101.200 6.048
201706 10.183 101.200 11.914
201709 18.192 101.800 21.158
201712 1.009 101.300 1.179
201803 0.279 101.700 0.325
201806 2.115 102.300 2.448
201809 5.530 102.400 6.394
201812 4.409 102.100 5.113
201903 3.947 102.900 4.542
201906 3.177 102.900 3.656
201909 4.504 102.900 5.182
201912 7.103 102.900 8.173
202003 8.947 103.300 10.255
202006 13.831 103.200 15.868
202009 10.598 103.500 12.124
202012 3.920 103.400 4.489
202103 9.000 104.300 10.217
202106 5.910 105.000 6.664
202109 7.162 105.800 8.015
202112 8.382 106.600 9.310
202203 4.590 109.900 4.945
202206 7.694 113.600 8.019
202209 16.577 116.400 16.862
202212 18.006 115.900 18.394
202303 16.966 117.300 17.125
202306 26.214 116.400 26.664
202309 17.778 117.400 17.929
202312 31.650 116.700 32.111
202403 10.897 118.400 10.897

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bavarian Nordic A/S  (OCSE:BAVA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bavarian Nordic A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bavarian Nordic A/S (OCSE:BAVA) Business Description

Traded in Other Exchanges
Address
Philip Heymans Alle 3, Hellerup, DNK, DK-2900
Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.

Bavarian Nordic A/S (OCSE:BAVA) Headlines

No Headlines